SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021

Author:

Mahasirimongkol Surakameth,Uppapong Ballang,Puangtubtim Wiroj,Dhepakson Panadda,Panyajai Parnuphan,Thawong Naphatcha,Pinyosukhee Nadthanan,Rojanawiwat Archawin,Wichukchinda Nuanjun,Soonthorncharttrawat Sakulrat,Larpardisorn Kanisorn,Amonyingcharoen Sumet,Juntaped Kritchai,Chaiyakum Tassanee,Tongkamsen Chayada,Srilaket Jeerapa,Chipatoom Jiratikamon,Wichajarn Rattanawadee,Chatchawankanpanich Nutchanat,Pattarapreeyakul Lapasrada,Chaiya Porntip,Mongkolsiri Kaveewan,Tuntigumthon Suthida,Sophondilok Kritsamon,Saengtong Nalinee,Jongpitisub Kodcharad,Sirilak Supakit

Abstract

Between the first case of COVID-19 in January 2020 and the end of 2021, Thailand experienced four waves of the epidemic. The third and fourth waves were caused by the alpha and delta strains from April 2021 to November 2021. Serosurveillance studies provide snapshots of the true scale of the outbreak, including the asymptomatic infections that could not be fully captured by a hospital-based case detection system. We aimed to investigate the distribution of SARs-CoV-2 seroprevalence in unvaccinated adults after the delta wave outbreak. From November to December 2021, we conducted a cross-sectional survey study in 12 public health areas (PHAs) across Thailand. A total of 26,717 blood samples were collected and tested for SARs-CoV-2 antibodies (anti-S IgG) using a qualitative immunoassay. The results showed that seropositive prevalence in this cohort was 1.4% (95% CI: 1.24 to 1.52). The lowest prevalence was in the northern region (PHA 1) and in central Thailand (PHA 3) at 0.4% (95% CI: 0.15 to 0.95), while the highest was in the southern region of Thailand (PHA 12) at 5.8% (95% CI: 4.48 to 7.29). This seropositive prevalence was strikingly lower than the reports from other countries. Our serosurveillance results suggest that the vaccination of unvaccinated groups should be accelerated, especially in the public health areas with the lowest seroprevalence.

Funder

the Department of Medical Science, Ministry of Public Health, Thailand

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3